Exemestane: beside a new treatment under test
34 studies: a new drug, cell therapy or vaccine is what the study tests. Page 1 of 1. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.
- Sapu003 in Advanced mTOR-sensitive Solid TumorsRecruitingNCT07369505Phase 1Report a problem
- A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 InhibitorsNot yet recruitingNCT07163481Phase 1Report a problem
- Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast CancerRecruitingNCT05573126Phase 1/2Report a problem
- GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast CancerTerminatedNCT02983604Phase 1/2Results postedReport a problem
- Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.CompletedNCT02732119Phase 1/2Results postedReport a problem
- Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast CancerCompletedNCT02392611Phase 1Results postedReport a problem
- Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast CancerCompletedNCT02049957Phase 2Results postedReport a problem
- BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid TumorsCompletedNCT01938846Phase 1Results postedReport a problem
- BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast CancerCompletedNCT01870505Phase 1Results postedReport a problem
- Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast CancerCompletedNCT01698918Phase 2Results postedReport a problem
- Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast CancerCompletedNCT01597193Phase 1Results postedReport a problem
- Ruxolitinib in Estrogen Receptor Positive Breast CancerCompletedNCT01594216Phase 2Results postedReport a problem
- Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer PatientsCompletedNCT01202591Phase 1/2Results postedReport a problem
- Exemestane With Sunitinib (SUTENT®) in Metastatic Breast CancerTerminatedNCT00905021Phase 1/2Results postedReport a problem
- A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast CancerTerminatedNCT00417885Phase 1/2Results postedReport a problem
- Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast CancerStatus unknownNCT05253066Phase 2/3Report a problem
- Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant TreatmentActive, not recruitingNCT05132790Not applicableReport a problem
- A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast CancerCompletedNCT04572295Phase 1Report a problem
- Neoadjuvant Tucidinostat and Exemestane in Early Breast CancerCompletedNCT04465097Phase 2Report a problem
- Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBCTerminatedNCT03361800Early Phase 1Report a problem
- Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast CancerCompletedNCT03308201Phase 1Report a problem
- A Study of LXI-15029 in Patients With Advanced Malignant Solid TumorsStatus unknownNCT03125746Phase 1Report a problem
- Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant ExposureCompletedNCT02997995Phase 2Report a problem
- Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast CancerTerminatedNCT02990845Phase 1/2Report a problem
- Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast CancerCompletedNCT02833155Phase 1Report a problem
- Study of KHK2375 in Subjects With Advanced or Recurrent Breast CancerCompletedNCT02623751Phase 1Report a problem
- Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic TumorsCompletedNCT02077933Phase 1Report a problem
- A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has SpreadActive, not recruitingNCT02057133Phase 1Report a problem
- A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT)TerminatedNCT02000375Phase 2Report a problem
- Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast CancerCompletedNCT01857193Phase 1Report a problem
- Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung CancerCompletedNCT01594398Phase 1Report a problem
- Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast CancerWithdrawnNCT01240941Phase 2Report a problem
- MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast CancerWithdrawnNCT01240928Phase 1Report a problem
- Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule FindingCompletedNCT01004081Phase 2Report a problem